Skip to content

Study · Non-randomized trial · n = 20 · 1998

7 results

Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.

Felberbaum RE, Germer U, Ludwig M, Riethmüller-Winzen H, Heise S, Buttge I, Bauer O, Reissmann T, Engel J, Diedrich K

Human reproduction (Oxford, England)1 Jun 1998Cited by 45 (Europe PMC)

PMID9688409 (opens in a new tab)DOI10.1093/humrep/13.6.1660 (opens in a new tab)PepBankPUB-09688409
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with uterine fibroids, cetrorelix satisfactorily suppressed gonadotrophins in sixteen patients.

    In plain wordsIn women with uterine fibroids, cetrorelix lowered gonadotrophins satisfactorily in sixteen patients.

    Peptide
    Cetrorelix
    Outcome
    DecreaseGonadotrophin suppression
    Study

    n = 20

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    60 mg initially, then 30 or 60 mg depot · intramuscular · 6 or 8 weeksAs given in this study (human).

    Measurements

    Patients with satisfactory suppression
    16 patients
    gonadotrophins suppression

    Source sentences

    Summary
    Sixteen patients showed satisfactory suppression of gonadotrophins and sex steroid secretion, avoiding any initial flare-up effect.
    4 context sentences
    Summary · context
    A depot preparation of the third-generation gonadotrophin-releasing hormone (GnRH) antagonist Cetrorelix (SB-75) was used for preoperative treatment in twenty premenopausal patients with symptomatic uterine fibroids who were to undergo surgery.
    Summary · context
    In a prospective, open, randomized setting 60 mg of Cetrorelix pamoate salt was administered i.m. on cycle day 2.
    Summary · context
    Patients were randomized for a second dose of 30 or 60 mg of Cetrorelix depot, which was administered according to the degree of oestradiol suppression (<50 pg/ml) on treatment day 21 or 28.
    Summary · context
    Surgery was done after 6 or 8 weeks of treatment, depending on second dosage administration.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with uterine fibroids, cetrorelix satisfactorily suppressed sex steroid secretion in sixteen patients.

    In plain wordsIn women with uterine fibroids, cetrorelix lowered sex steroid secretion satisfactorily in sixteen patients.

    Peptide
    Cetrorelix
    Outcome
    DecreaseSex steroid suppression
    Study

    n = 20

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    60 mg initially, then 30 or 60 mg depot · intramuscular · 6 or 8 weeksAs given in this study (human).

    Measurements

    Patients with satisfactory suppression
    16 patients
    sex steroid secretion suppression

    Source sentences

    Summary
    Sixteen patients showed satisfactory suppression of gonadotrophins and sex steroid secretion, avoiding any initial flare-up effect.
    4 context sentences
    Summary · context
    A depot preparation of the third-generation gonadotrophin-releasing hormone (GnRH) antagonist Cetrorelix (SB-75) was used for preoperative treatment in twenty premenopausal patients with symptomatic uterine fibroids who were to undergo surgery.
    Summary · context
    In a prospective, open, randomized setting 60 mg of Cetrorelix pamoate salt was administered i.m. on cycle day 2.
    Summary · context
    Patients were randomized for a second dose of 30 or 60 mg of Cetrorelix depot, which was administered according to the degree of oestradiol suppression (<50 pg/ml) on treatment day 21 or 28.
    Summary · context
    Surgery was done after 6 or 8 weeks of treatment, depending on second dosage administration.
  3. 03HumanNon-randomized trialSafety outcome

    In women with uterine fibroids and satisfactory hormone suppression, cetrorelix avoided initial flare-up.

    In plain wordsIn women with uterine fibroids and satisfactory hormone suppression, no initial flare-up occurred with cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    Not applicableInitial flare-up
    Study

    n = 16

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    60 mg initially, then 30 or 60 mg depot · intramuscular · 6 or 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Sixteen patients showed satisfactory suppression of gonadotrophins and sex steroid secretion, avoiding any initial flare-up effect.
    4 context sentences
    Summary · context
    A depot preparation of the third-generation gonadotrophin-releasing hormone (GnRH) antagonist Cetrorelix (SB-75) was used for preoperative treatment in twenty premenopausal patients with symptomatic uterine fibroids who were to undergo surgery.
    Summary · context
    In a prospective, open, randomized setting 60 mg of Cetrorelix pamoate salt was administered i.m. on cycle day 2.
    Summary · context
    Patients were randomized for a second dose of 30 or 60 mg of Cetrorelix depot, which was administered according to the degree of oestradiol suppression (<50 pg/ml) on treatment day 21 or 28.
    Summary · context
    Surgery was done after 6 or 8 weeks of treatment, depending on second dosage administration.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with satisfactory hormone suppression, ultrasound showed mean largest-fibroid shrinkage of 33.5% at the end of cetrorelix treatment.

    In plain wordsIn women with satisfactory hormone suppression, ultrasound showed average largest-fibroid shrinkage of 33.5% at the end of cetrorelix treatment.

    Peptide
    Cetrorelix
    Outcome
    DecreaseLargest fibroid shrinkage at treatment end
    Study

    n = 16

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    60 mg initially, then 30 or 60 mg depot · intramuscular · 6 or 8 weeksAs given in this study (human).

    Measurements

    Mean shrinkage
    33.5%
    treatment end, TVS

    Source sentences

    Summary
    In these patients a mean shrinkage rate of largest fibroid volume of 33.5% at the end of treatment could be observed according to TVS, while the mean shrinkage rate obtained after 14 days of treatment was 31.3%.
    5 context sentences
    Summary · context
    Sixteen patients showed satisfactory suppression of gonadotrophins and sex steroid secretion, avoiding any initial flare-up effect.
    Summary · context
    A depot preparation of the third-generation gonadotrophin-releasing hormone (GnRH) antagonist Cetrorelix (SB-75) was used for preoperative treatment in twenty premenopausal patients with symptomatic uterine fibroids who were to undergo surgery.
    Summary · context
    In a prospective, open, randomized setting 60 mg of Cetrorelix pamoate salt was administered i.m. on cycle day 2.
    Summary · context
    Patients were randomized for a second dose of 30 or 60 mg of Cetrorelix depot, which was administered according to the degree of oestradiol suppression (<50 pg/ml) on treatment day 21 or 28.
    Summary · context
    Surgery was done after 6 or 8 weeks of treatment, depending on second dosage administration.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with satisfactory hormone suppression, mean largest-fibroid shrinkage after 14 days of cetrorelix was 31.3%.

    In plain wordsIn women with satisfactory hormone suppression, average largest-fibroid shrinkage after 14 days of cetrorelix was 31.3%.

    Peptide
    Cetrorelix
    Outcome
    DecreaseLargest fibroid shrinkage after 14 days
    Study

    n = 16

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    60 mg initially, then 30 or 60 mg depot · intramuscular · 6 or 8 weeksAs given in this study (human).

    Measurements

    Mean shrinkage
    31.3%
    14 days, TVS

    Source sentences

    Summary
    In these patients a mean shrinkage rate of largest fibroid volume of 33.5% at the end of treatment could be observed according to TVS, while the mean shrinkage rate obtained after 14 days of treatment was 31.3%.
    5 context sentences
    Summary · context
    Sixteen patients showed satisfactory suppression of gonadotrophins and sex steroid secretion, avoiding any initial flare-up effect.
    Summary · context
    A depot preparation of the third-generation gonadotrophin-releasing hormone (GnRH) antagonist Cetrorelix (SB-75) was used for preoperative treatment in twenty premenopausal patients with symptomatic uterine fibroids who were to undergo surgery.
    Summary · context
    In a prospective, open, randomized setting 60 mg of Cetrorelix pamoate salt was administered i.m. on cycle day 2.
    Summary · context
    Patients were randomized for a second dose of 30 or 60 mg of Cetrorelix depot, which was administered according to the degree of oestradiol suppression (<50 pg/ml) on treatment day 21 or 28.
    Summary · context
    Surgery was done after 6 or 8 weeks of treatment, depending on second dosage administration.
  6. 06HumanNon-randomized trialEfficacy outcome

    In good responders with uterine fibroids, largest fibroid volume at day 14 of cetrorelix was approximately 56.7% of baseline.

    In plain wordsIn good responders with uterine fibroids, the largest fibroid reached approximately 56.7% of baseline volume at day 14 of cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    DecreaseLargest fibroid volume in good responders
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    60 mg initially, then 30 or 60 mg depot · intramuscular · 6 or 8 weeksAs given in this study (human).

    Measurements

    Residual volume
    ≈ 56.7%
    day 14

    Source sentences

    Summary
    In good responders (shrinkage >20%) largest fibroid volume at day 14 was approximately 56.7% of basic assessment.
    4 context sentences
    Summary · context
    A depot preparation of the third-generation gonadotrophin-releasing hormone (GnRH) antagonist Cetrorelix (SB-75) was used for preoperative treatment in twenty premenopausal patients with symptomatic uterine fibroids who were to undergo surgery.
    Summary · context
    In a prospective, open, randomized setting 60 mg of Cetrorelix pamoate salt was administered i.m. on cycle day 2.
    Summary · context
    Patients were randomized for a second dose of 30 or 60 mg of Cetrorelix depot, which was administered according to the degree of oestradiol suppression (<50 pg/ml) on treatment day 21 or 28.
    Summary · context
    Surgery was done after 6 or 8 weeks of treatment, depending on second dosage administration.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women with uterine fibroids, MRI showed mean shrinkage during cetrorelix treatment of 25.4% of initial volume.

    In plain wordsIn women with uterine fibroids, MRI showed average shrinkage during cetrorelix treatment of 25.4% of initial volume.

    Peptide
    Cetrorelix
    Outcome
    DecreaseMRI fibroid shrinkage
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    60 mg initially, then 30 or 60 mg depot · intramuscular · 6 or 8 weeksAs given in this study (human).

    Measurements

    Mean shrinkage
    25.4%
    MRI

    Source sentences

    Summary
    Although MRI showed minor mean shrinkage rates of only 25.4% of the initial volume, these differences in comparison to TVS assessment were not statistically significant.
    4 context sentences
    Summary · context
    A depot preparation of the third-generation gonadotrophin-releasing hormone (GnRH) antagonist Cetrorelix (SB-75) was used for preoperative treatment in twenty premenopausal patients with symptomatic uterine fibroids who were to undergo surgery.
    Summary · context
    In a prospective, open, randomized setting 60 mg of Cetrorelix pamoate salt was administered i.m. on cycle day 2.
    Summary · context
    Patients were randomized for a second dose of 30 or 60 mg of Cetrorelix depot, which was administered according to the degree of oestradiol suppression (<50 pg/ml) on treatment day 21 or 28.
    Summary · context
    Surgery was done after 6 or 8 weeks of treatment, depending on second dosage administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.